Acta Pharmaceutica Sinica B,
Journal Year:
2024,
Volume and Issue:
14(7), P. 2854 - 2868
Published: March 15, 2024
Single-domain
antibodies
(sdAbs),
initially
identified
in
camelids
or
sharks
and
commonly
referred
to
as
nanobodies
VNARs,
have
emerged
a
promising
alternative
conventional
therapeutic
antibodies.
These
sdAbs
many
superior
physicochemical
pharmacological
properties,
including
small
size,
good
solubility
thermostability,
easier
accessible
epitopes,
strong
tissue
penetration.
However,
the
inherent
challenges
associated
with
animal
origin
of
limit
their
clinical
use.
In
recent
years,
various
innovative
humanization
technologies,
complementarity-determining
region
(CDR)
grafting
complete
engineering
fully
human
sdAbs,
been
developed
mitigate
potential
immunogenicity
issues
enhance
compatibility.
This
review
provides
comprehensive
exploration
emphasizing
distinctive
features
progress
methodologies.
addition,
we
provide
an
overview
developing
drugs
strategies
based
on
solid
tumor
treatment,
such
sdAb-drug
conjugates,
multispecific
sdAb-based
delivery
systems,
cell
therapy.
Biomedicines,
Journal Year:
2024,
Volume and Issue:
12(9), P. 2158 - 2158
Published: Sept. 23, 2024
Cancer
immunotherapy
has
emerged
as
a
transformative
approach
in
oncology,
utilizing
the
body’s
immune
system
to
specifically
target
and
destroy
malignant
cells.
This
review
explores
scope
impact
of
various
immunotherapeutic
strategies,
including
monoclonal
antibodies,
chimeric
antigen
receptor
(CAR)-T
cell
therapy,
checkpoint
inhibitors,
cytokine
therapeutic
vaccines.
Monoclonal
such
Rituximab
Trastuzumab,
have
revolutionized
treatment
paradigms
for
lymphoma
breast
cancer
by
offering
targeted
interventions
that
reduce
off-target
effects.
CAR-T
therapy
presents
potentially
curative
option
refractory
hematologic
malignancies,
although
challenges
remain
effectively
treating
solid
tumors.
Checkpoint
inhibitors
redefined
management
cancers
like
melanoma
lung
cancer;
however,
managing
immune-related
adverse
events
ensuring
durable
responses
are
critical
areas
focus.
Cytokine
continues
play
vital
role
modulating
response,
with
advancements
engineering
improving
specificity
reducing
systemic
toxicity.
Therapeutic
vaccines,
particularly
mRNA-based
represent
frontier
personalized
treatment,
aiming
generate
robust,
long-lasting
against
tumor-specific
antigens.
Despite
these
advancements,
field
faces
significant
challenges,
resistance,
tumor
heterogeneity,
immunosuppressive
microenvironment.
Future
research
should
address
obstacles
through
emerging
technologies,
next-generation
Clustered
Regularly
Interspaced
Short
Palindromic
Repeat
(CRISPR)-based
gene
editing,
AI-driven
drug
discovery.
By
integrating
novel
approaches,
holds
promise
more
durable,
less
toxic,
highly
options,
ultimately
patient
outcomes
survival
rates.
Chemical Reviews,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 22, 2025
Throughout
history,
we
have
looked
to
nature
discover
and
copy
pharmaceutical
solutions
prevent
heal
diseases.
Due
the
advances
in
metabolic
engineering
production
of
proteins
different
host
cells,
moved
from
mimicking
delicate
cells
proteins.
We
can
now
produce
novel
drug
molecules,
which
are
fusions
small
chemical
drugs
Currently
at
brink
yet
another
step
venture
beyond
nature's
border
with
use
unnatural
amino
acids
manufacturing
without
living
using
cell-free
systems.
In
this
review,
summarize
progress
limitations
last
decades
development
protein
development,
also
discuss
possible
future
directions
field.
Journal of Immunotherapy and Precision Oncology,
Journal Year:
2025,
Volume and Issue:
8(2), P. 108 - 112
Published: Feb. 1, 2025
Antibody-drug
conjugates
(ADCs)
are
a
potent
class
of
antineoplastic
drugs
that
deliver
cytotoxic
agents
via
targeting
with
monoclonal
antibodies;
however,
ADCs
associated
high
rates
lung
toxicities,
limiting
the
therapeutic
potential
in
many
patients.
We
report
case
patient
metastatic
non-small
cell
cancer
taking
ADC
telisotuzumab
vedotin
(Teliso
V)
plus
osimtertinib
who
developed
ADC-induced
pneumonitis
despite
clinical
benefit.
This
was
able
to
tolerate
treatment
for
prolonged
period
on
novel
steroid
regimen,
using
steroids
when
asymptomatic
but
radiologically
evident
and
as
daily
suppressant.
strategy
may
have
implications
broader
management
ADC-interstitial
disease/pneumonitis
underscores
its
mechanisms.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(13), P. 2420 - 2420
Published: June 30, 2024
Antibody-drug
conjugates
(ADCs)
have
been
a
significant
advancement
in
cancer
therapy,
particularly
for
urothelial
(UC).
These
innovative
treatments,
originally
developed
hematological
malignancies,
use
target-specific
monoclonal
antibodies
linked
to
potent
cytotoxic
agents.
This
rational
drug
design
efficiently
delivers
cell-killing
agents
cells
expressing
specific
surface
proteins,
which
are
abundant
UC
owing
their
high
antigen
expression.
is
an
ideal
candidate
ADC
as
it
enhances
on-target
efficacy
while
mitigating
systemic
toxicity.
In
recent
years,
considerable
progress
has
made
understanding
the
biology
and
mechanisms
of
tumor
progression
UC.
However,
despite
introduction
immune
checkpoint
inhibitors,
advanced
characterized
by
rapid
poor
survival
rates.
Targeted
therapies
that
include
anti-nectin
4
enfortumab
vedotin
fibroblast
growth
factor
receptor
inhibitor
erdafitinib.
Enfortumab
shown
prospective
studies
patients
with
UC,
alone
combination
pembrolizumab.
The
anti-Trop-2
sacituzumab
govitecan
also
demonstrated
effectiveness
single-armed
studies.
review
highlights
mechanism
action
ADCs,
application
mono-
therapies,
primary
resistance,
future
perspectives
clinical
treatment.
ADCs
proven
be
increasingly
vital
component
therapeutic
landscape
carcinoma,
filling
gap
treatment
this
progressive
disease.
MedComm,
Journal Year:
2024,
Volume and Issue:
5(8)
Published: July 28, 2024
Abstract
Antibody–drug
conjugates
(ADCs)
consist
of
monoclonal
antibodies
that
target
tumor
cells
and
cytotoxic
drugs
linked
through
linkers.
By
leveraging
antibodies’
targeting
properties,
ADCs
deliver
into
via
endocytosis
after
identifying
the
antigen.
This
precise
method
aims
to
kill
selectively
while
minimizing
harm
normal
cells,
offering
safe
effective
therapeutic
benefits.
Recent
years
have
seen
significant
progress
in
antitumor
treatment
with
ADC
development,
providing
patients
new
potent
options.
With
over
300
explored
for
various
indications
some
already
approved
clinical
use,
challenges
such
as
resistance
due
factors
like
antigen
expression,
processing,
payload
emerged.
review
outline
history
their
structure,
mechanism
action,
recent
composition
advancements,
selection,
completed
ongoing
trials,
mechanisms,
intervention
strategies.
Additionally,
it
will
delve
potential
novel
markers,
linkers,
payloads,
innovative
action
mechanisms
enhance
cancer
The
evolution
has
also
led
emergence
combination
therapy
a
approach
improve
drug
efficacy.
